Performance analysis of EyePoint Pharmaceuticals (EYPT)
Annual Return
Over the past 3 years, EYPT has had an average annual return of +27.31%, outperforming the benchmark SPY, which returned +22.45% annual.
Over the past 5 years, EYPT has had an average annual return of +6.16%, underperforming the benchmark SPY, which returned +13.88% annual.
Over the past 10 years, EYPT has had an average annual return of -9.93%, underperforming the benchmark SPY, which returned +15.45% annual.
Since Jan 27, 2005, EYPT has had an average annual return of -9.35%, underperforming the benchmark SPY, which returned +11.11% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.47% | +145.28% | -67.77% | +559.60% | -71.37% | +86.11% | -57.58% | -17.96% | +74.91% | -36.82% | -64.53% | +17.27% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | ||
| +3.54% | +228.13% | +8.95% | -78.27% | +42.34% | +282.05% | +18.93% | -59.47% | -63.89% | -46.22% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.99% | +29.84% | -26.59% | +2.41% | +2.89% | -9.16% | -32.47% | ||||||
| 2025 | +2.70% | -17.98% | -13.60% | +25.74% | +6.19% | +29.96% | +4.38% | +17.79% | +23.09% | -8.04% | +13.27% | +23.22% | +145.28% |
| 2024 | +16.51% | +1.04% | -24.02% | -14.86% | -39.13% | -18.74% | +13.49% | -9.45% | -10.66% | +47.11% | -24.77% | -15.78% | -67.77% |
| 2023 | +32.95% | -28.23% | -12.01% | +113.31% | -3.52% | +43.78% | +43.60% | -20.72% | -19.35% | -24.62% | +3.83% | +269.50% | +559.60% |
| 2022 | -23.46% | +6.22% | +22.10% | -7.02% | -14.58% | -18.42% | +15.94% | +9.57% | -20.88% | -31.73% | -40.71% | +9.40% | -71.37% |
| 2021 | +70.38% | -3.49% | -6.04% | +5.24% | -8.08% | -8.58% | -8.49% | +33.09% | -4.77% | +10.02% | +37.83% | -22.55% | +86.11% |
| 2020 | +20.66% | -31.03% | -20.93% | -4.92% | -11.28% | -11.67% | -6.61% | -24.61% | -3.19% | -27.71% | +45.58% | +20.63% | -57.58% |
| 2019 | +15.89% | +18.75% | -31.16% | -4.49% | -8.16% | +4.41% | -15.25% | +7.95% | +20.68% | +24.85% | -31.85% | +0.65% | -17.96% |
| 2018 | +5.48% | -7.84% | +16.16% | +101.65% | -11.80% | -4.12% | +9.12% | -3.54% | +63.04% | -40.07% | +10.32% | -19.95% | +74.91% |
| 2017 | +2.94% | -0.57% | -1.72% | +0% | +31.99% | -24.68% | -28.07% | -1.63% | -0.83% | -2.51% | +7.73% | -14.26% | -36.82% |
Drawdown analysis of EyePoint Pharmaceuticals (EYPT)
The maximum drawdown for the EYPT was -97.73%, occurring on Mar 24, 2023. This drawdown has not yet recovered.
The current EYPT drawdown is -87.71%.
Since Jan 27, 2005 EYPT has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.73% | Jan 27, 2005 | 4567 | Mar 24, 2023 | Ongoing | Ongoing | Ongoing |